ArticleCardiovascular drugs and therapy2022
Chronic Oral Anticoagulation and Clinical Outcome in Hospitalized COVID-19 Patients.
Article in Cardiovascular drugs and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 25 citations in OpenAlex.
- The effect of previous oral anticoagulant use on clinical outcomes in COVID-19: A systematic review and meta-analysis.The American journal of emergency medicine · 2022Pooled it
- The Use of Oral Anticoagulation Is Not Associated With a Reduced Risk of Mortality in Patients With COVID-19: A Systematic Review and Meta-Analysis of Cohort Studies.Frontiers in pharmacology · 2022Pooled it
- Continuation of direct oral anticoagulants versus warfarin during critical illness: bleeding and clinical outcomes in a multicenter ICU cohort.Journal of thrombosis and thrombolysis · 2026Article
- Article
- Roles of oral anticoagulant use on the risk of 28-day mortality and in-hospital mortality in patients with acute respiratory distress syndrome.Frontiers in pharmacology · 2025Article
- Anticoagulant use before COVID-19 diagnosis prevent COVID-19 associated acute venous thromboembolism or not: A systematic review and meta-analysis.World journal of methodology · 2024Article
- Thromboembolic Disease and COVID-19: Experience of a University and Emergency Hospital During the Pandemic.Cureus · 2024Article
- Anticoagulant therapy in COVID-19: A narrative review.Clinical and translational science · 2023Review
- Gender Differences in Atrial Fibrillation: From the Thromboembolic Risk to the Anticoagulant Treatment Response.Medicina (Kaunas, Lithuania) · 2023Review
- Article
- Risk of thrombotic events and other complications in anticoagulant users infected with SARS-CoV-2: an observational cohort study in primary health care in SIDIAP (Catalonia, Spain).BMC primary care · 2022Observational
- Clinical Outcome of Hospitalized COVID-19 Patients with History of Atrial Fibrillation.Medicina (Kaunas, Lithuania) · 2022Article
- Long-Term Prognostic Impact of Right Ventricular Dysfunction in Patients with COVID-19.Journal of personalized medicine · 2022Article
- Acute Coronary Syndrome in Patients with SARS-CoV-2 Infection: Pathophysiology and Translational Perspectives.Translational medicine @ UniSa · 2022Article
- Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors.Frontiers in cardiovascular medicine · 2022Article
- Prognostic Implications of Right Ventricular Function and Pulmonary Pressures Assessed by Echocardiography in Hospitalized Patients with COVID-19.Journal of personalized medicine · 2021Article
- The Challenges of ST-Elevation Myocardial Infarction in COVID-19 Patients.Case reports in cardiology · 2021Article
- COVID-19 and Acute Coronary Syndromes: From Pathophysiology to Clinical Perspectives.Oxidative medicine and cellular longevity · 2021Review
- The effect of oral anticoagulant use before visit for patients with COVID-19 on mortality: A meta-analysis.Tzu chi medical journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe clinical course of COVID-19 may be complicated by acute respiratory distress syndrome (ARDS) and thromboembolic events, which are associated with high risk of mortality. Although previous studies reported a lower rate of death in patients treated with heparin, the potential benefit of chronic oral anticoagulation therapy (OAT) remains unknown. We aimed to investigate the association between OAT with the risk of ARDS and mortality in hospitalized patients with COVID-19.
methodsThis is a multicenter retrospective Italian study including consecutive patients hospitalized for COVID-19 from March 1 to April 22, 2020, at six Italian hospitals. Patients were divided into two groups according to the chronic assumption of oral anticoagulants.
resultsOverall, 427 patients were included; 87 patients (19%) were in the OAT group. Of them, 54 patients (13%) were on treatment with non-vitamin k oral anticoagulants (NOACs) and 33 (8%) with vitamin-K antagonists (VKAs). OAT patients were older and had a higher rate of hypertension, diabetes, and coronary artery disease compared to No-OAT group. The rate of ARDS at admission (26% vs 28%, P=0.834), or developed during the hospitalization (9% vs 10%, P=0.915), was similar between study groups; in-hospital mortality (22% vs 26%, P=0.395) was also comparable. After balancing for potential confounders by using the propensity score matching technique, no differences were found in term of clinical outcome between OAT and No-OAT patients
conclusionOral anticoagulation therapy, either NOACs or VKAs, did not influence the risk of ARDS or death in patients hospitalized with COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.